William Blair began coverage on shares of Cambrex (NYSE:CBM) in a research report released on Tuesday, MarketBeat.com reports. The brokerage issued an outperform rating on the biotechnology company’s stock. William Blair also issued estimates for Cambrex’s Q4 2017 earnings at $1.09 EPS, FY2017 earnings at $2.96 EPS, FY2018 earnings at $2.95 EPS, FY2019 earnings at $3.13 EPS, FY2020 earnings at $3.32 EPS and FY2021 earnings at $3.61 EPS.
Several other research firms also recently weighed in on CBM. Craig Hallum reaffirmed a buy rating and issued a $60.00 price objective (down from $70.00) on shares of Cambrex in a research note on Tuesday, October 31st. Zacks Investment Research raised Cambrex from a strong sell rating to a hold rating in a research note on Monday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $60.50.
Cambrex (NYSE:CBM) traded up $2.30 during midday trading on Tuesday, reaching $56.00. The company had a trading volume of 462,700 shares, compared to its average volume of 301,300. Cambrex has a 12-month low of $42.55 and a 12-month high of $62.95. The stock has a market cap of $1,760.16, a P/E ratio of 18.67, a P/E/G ratio of 1.28 and a beta of 2.27.
Large investors have recently made changes to their positions in the business. Stifel Financial Corp grew its holdings in Cambrex by 0.8% during the 2nd quarter. Stifel Financial Corp now owns 4,580 shares of the biotechnology company’s stock valued at $275,000 after buying an additional 37 shares during the last quarter. Piedmont Investment Advisors LLC acquired a new stake in Cambrex during the 2nd quarter valued at $421,000. Tributary Capital Management LLC grew its holdings in Cambrex by 22.3% during the 3rd quarter. Tributary Capital Management LLC now owns 232,919 shares of the biotechnology company’s stock valued at $12,811,000 after buying an additional 42,428 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Cambrex by 117.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 231,931 shares of the biotechnology company’s stock valued at $12,721,000 after buying an additional 125,062 shares during the last quarter. Finally, California Public Employees Retirement System grew its holdings in Cambrex by 4.4% during the 2nd quarter. California Public Employees Retirement System now owns 73,500 shares of the biotechnology company’s stock valued at $4,392,000 after buying an additional 3,100 shares during the last quarter.
TRADEMARK VIOLATION NOTICE: “Cambrex (CBM) Now Covered by William Blair” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.com-unik.info/2018/01/19/cambrex-cbm-now-covered-by-william-blair.html.
Cambrex Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.